15,000 COVID-19 tests produced by McGill University and the RI-MUHC: a step toward Canadian self-sufficiency
In July 2020, the McGill University Health Centre’s (MUHC's) Department of Clinical...
Protecting lung cancer patients from COVID-19 – and learning from the experience
A study led by Dr. Nathaniel Bourganim tracked changes in treatment plans
New study of therapy options in metastatic melanoma
RI-MUHC researchers lead “real-world” analysis of treatment patterns with checkpoint inhibitors
Nip it in the bud: New study will attack SARS-Cov2 where it multiplies
RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening
Serious Flaws in Studies Linking COVID-19 and Air Pollution
Studies have yet to prove this link, say Carleton and McGill University epidemiologists
Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations
COVID-19 Q&A on dealing with pandemic fatigue
“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley
New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk
RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study
Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide
Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet